Evidence map›Paper›PMID 27940637›Full record

ArticleMolecular & cellular proteomics : MCP2017

An Optimized Chromatographic Strategy for Multiplexing In Parallel Reaction Monitoring Mass Spectrometry: Insights from Quantitation of Activated Kinases.

Anatoly Urisman, Rebecca S Levin, John D Gordan, James T Webber, Hilda Hernandez, Yasushi Ishihama, Kevan M Shokat, Alma L Burlingame

Open access · hybridAbstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. A Constellation of Fluorescent Biosensors to Illuminate the Galaxy of Protein Kinases.Chembiochem : a European journal of chemical biology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. An Introduction to Advanced Targeted Acquisition Methods.Molecular & cellular proteomics : MCP · 2021
    Review
  13. Article
  14. Article
  15. Proteomic Changes of Porcine Oocytes After Vitrification and SubsequentFrontiers in cell and developmental biology · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Anatoly UrismanFrom the ‡Department of Pathology, University of California San Francisco, San Francisco, California; anatoly.urisman@ucsf.edu.ORCID 0000-0001-8364-5303
Rebecca S Levin§Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California.
John D Gordan¶Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, California.
James T Webber**Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California.
Hilda Hernandez§Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California.
Yasushi Ishihama‡‡Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
Kevan M Shokat¶Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, California.
Alma L Burlingame§Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California.
University of California, San Francisco · USKyoto Pharmaceutical University · JP

Funding

Molecular and Cellular Mechanisms in CancerT32CA108462 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2004 to 2024
$10.4M
RESEARCH TRAINING IN CHEMISTRY AND CHEMICAL BIOLOGYT32GM064337 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT · 2002 to 2021
$7.8M
Bio-Organic Biomedical Mass Spectromy ResourceP41GM103481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BURLINGAME, ALMA L · 2012 to 2015
$6.4M
Integrative Program in Complex Biological System (ipCBS)T32EB009383 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARSHALL, WALLACE, WEINER, ORION D · 2009 to 2022
$3.2M
Purchase of Q-Exactive Mass SpectrometerS10OD016229 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BURLINGAME, ALMA L · 2013 to 2013
$507k
Howard Hughes Medical InstituteNCI NIH HHS T32 CA108462NIBIB NIH HHS T32 EB009383NIGMS NIH HHS P41 GM103481NIGMS NIH HHS T32 GM064337NIH HHS S10 OD016229
6 · The paper itself

Abstract

Reliable quantitation of protein abundances in defined sets of cellular proteins is critical to numerous biological applications. Traditional immunodetection-based methods are limited by the quality and availability of specific antibodies, especially for site-specific post-translational modifications. Targeted proteomic methods, including the recently developed parallel reaction monitoring (PRM) mass spectrometry, have enabled accurate quantitative measurements of up to a few hundred specific target peptides. However, the degree of practical multiplexing in label-free PRM workflows remains a significant limitation for the technique. Here we present a strategy for significantly increasing multiplexing in label-free PRM that takes advantage of the superior separation characteristics and retention time stability of meter-scale monolithic silica-C18 column-based chromatography. We show the utility of the approach in quantifying kinase abundances downstream of previously developed active kinase enrichment methodology based on multidrug inhibitor beads. We examine kinase activation dynamics in response to three different MAP kinase inhibitors in colorectal carcinoma cells and demonstrate reliable quantitation of over 800 target peptides from over 150 kinases in a single label-free PRM run. The kinase activity profiles obtained from these analyses reveal compensatory activation of TGF-β family receptors as a response to MAPK blockade. The gains achieved using this label-free PRM multiplexing strategy will benefit a wide array of biological applications.

Indexed as

AnimalsCell Line, TumorChromatography, LiquidColorectal NeoplasmsEnzyme ActivationHCT116 CellsHumansMass SpectrometryMicePeptidesPhosphotransferasesProtein Kinase InhibitorsProteomicsWorkflowPeptidesPhosphotransferasesProtein Kinase Inhibitors

Identifiers

PMID27940637
PMCPMC5294213
OpenAlexW2560011493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.